No Data
No Data
The Market Lifts Liaoning Oxiranchem,Inc. (SZSE:300082) Shares 32% But It Can Do More
Liaoning Oxiranchem, Inc. (300082.SZ): The solid-state electrolyte material PEO is still in the application development stage and there is currently no financing demand.
On August 16, Gelonhui reported that Liaoning Oxiranchem, Inc. (300082.SZ) stated on the investor interactive platform that the company's solid electrolyte material PEO is still in the application development stage and does not currently involve financing requirements.
Liaoning Oxiranchem, Inc. (300082.SZ): Oxiranchem has always been committed to the development and application of high-purity epoxy ethane derivative auxiliary materials in the field of medical and health.
Liaoning OxiranChem, Inc. (300082.SZ), on the investor interaction platform on August 16, stated that its wholly-owned subsidiary Aoke Pharmaceutical is a leading domestic enterprise that produces pharmaceutical grade polyethylene glycol in compliance with regulations. It has always been committed to the development and application of high-purity epoxy ethane derivatives as excipients in the pharmaceutical and health fields. At present, its PEG products are mainly used as active pharmaceutical ingredients and pharmaceutical excipients; the company's existing products are different from Jenkem Technology's application direction.
liaoning oxiranchem,inc (300082.SZ): Its main customers for pharmaceutical PEG include related enterprises of cardiovascular and cerebrovascular diseases, viral influenza, and intestinal cleansing and constipation type pharmaceutical preparations.
On August 16th, Gelunhui reported that Liaoning Oxiranchem, Inc. (300082.SZ) stated on its investor interaction platform that the company's main customers for medicinal PEG include related enterprises in the field of cardiovascular and cerebrovascular diseases, viral influenza, intestinal cleansing and laxative pharmaceutical preparations, and has not yet cooperated with anti-tumor pharmaceutical companies.
Liaoning Oxiranchem, Inc. (300082.SZ): Currently not cooperating with anti-tumor pharmaceutical companies.
On August 13th, Gelunhui reported that Liaoning Oxiranchem, Inc. (300082.SZ) stated on the investor communication platform that the main customers of the company's medicinal PEG mainly include related enterprises of cardiovascular and cerebrovascular diseases, viral influenza, intestinal cleansing and constipation types of pharmaceutical preparations, and currently there is no cooperation with anti-tumor pharmaceutical companies.
Liaoning Oxiranchem,Inc (300082.SZ): Cooperation with Sinopec is being carried out normally and is not affected by anything.
On August 9, Glon Hui reported that Liaoning Oxiranchem, Inc. (300082.SZ) stated at an investor relations event that the Tianjin project failed to cooperate due to significant changes in the market environment of the cooperative project, and many related preparatory work agreed upon by both parties could not be completed as scheduled, making it impossible to achieve the cooperation purpose stipulated in the joint venture contract. However, as the largest strategic customer of China Petroleum & Chemical Corporation in the epoxy ethane industry chain, the two parties have maintained close cooperation in the upstream and downstream of the petrochemical industry chain. Our cooperation with Sinopec is being carried out normally and is not affected in any way. At the same time, trend-oriented loss reduction and efficiency improvement are the company's key focus this year.
No Data